Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W.

Nat Med. 2003 May;9(5):562-7. Epub 2003 Apr 21.

PMID:
12704383
2.

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.

Thompson RH, Dong H, Kwon ED.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. Review.

3.

B7-H1 pathway and its role in the evasion of tumor immunity.

Dong H, Chen L.

J Mol Med (Berl). 2003 May;81(5):281-7. Epub 2003 Apr 30. Review.

PMID:
12721664
4.

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Blank C, Gajewski TF, Mackensen A.

Cancer Immunol Immunother. 2005 Apr;54(4):307-14. Epub 2004 Dec 15. Review.

PMID:
15599732
5.

Significance of B7-H1 overexpression in kidney cancer.

Thompson RH, Kwon ED.

Clin Genitourin Cancer. 2006 Dec;5(3):206-11. Review.

PMID:
17239274
6.

B7 family molecules: novel immunomodulators at the maternal-fetal interface.

Petroff MG, Chen L, Phillips TA, Hunt JS.

Placenta. 2002 Apr;23 Suppl A:S95-101. Review. Erratum in: Placenta. 2003 Jan;24(1):122..

PMID:
11978065
7.

Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis.

Cao Y, Zhang L, Ritprajak P, Tsushima F, Youngnak-Piboonratanakit P, Kamimura Y, Hashiguchi M, Azuma M.

Cancer Res. 2011 Jul 15;71(14):4737-41. doi: 10.1158/0008-5472.CAN-11-0527. Epub 2011 Jul 5. Review.

8.

Immunology of B7-H1 and its roles in human diseases.

Tamura H, Ogata K, Dong H, Chen L.

Int J Hematol. 2003 Nov;78(4):321-8. Review.

PMID:
14686489
9.

Immunopathogenesis of ovarian cancer.

Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK.

Minerva Med. 2009 Oct;100(5):385-400. Review.

PMID:
19910891
10.

Therapeutic targeting of B7-H1 in breast cancer.

Hasan A, Ghebeh H, Lehe C, Ahmad R, Dermime S.

Expert Opin Ther Targets. 2011 Oct;15(10):1211-25. doi: 10.1517/14728222.2011.613826. Epub 2011 Aug 28. Review.

PMID:
21870995
11.

Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M.

Expert Opin Biol Ther. 2011 Apr;11(4):441-5. doi: 10.1517/14712598.2011.554812. Epub 2011 Jan 28. Review.

12.

Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity.

Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD.

Immunotherapy. 2011 Jan;3(1):77-96. doi: 10.2217/imt.10.95. Review.

PMID:
21174559
13.

Inhibitory B7 family members in human ovarian carcinoma.

Wei S, Curiel T, Coukos G, Liu R, Zou W.

Adv Exp Med Biol. 2008;622:261-71. doi: 10.1007/978-0-387-68969-2_21. Review. No abstract available.

PMID:
18546634

Supplemental Content

Support Center